Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Bypassing nonparallelism of a monoclonal antibody ligand-binding assay by employment of alternative assay formats.

Kiesgen S, Schröder A, Schwarz T, Czupalla O, Braun M, Gnoth MJ, Grudzinska-Goebel J.

Bioanalysis. 2016 Dec;8(24):2581-2593.

PMID:
27884079
2.

Determination of nifurtimox in dog plasma by stable-isotope dilution LC-MS/MS.

Gnoth MJ, Hopfe PM, Thuss U.

Bioanalysis. 2015 Nov;7(21):2777-87. doi: 10.4155/bio.15.185. Epub 2015 Nov 13.

PMID:
26564573
3.

Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS.

Gnoth MJ, Hopfe PM, Czembor W.

Bioanalysis. 2015;7(2):193-205. doi: 10.4155/bio.14.257.

PMID:
25587836
4.

Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.

Swift B, Nebot N, Lee JK, Han T, Proctor WR, Thakker DR, Lang D, Radtke M, Gnoth MJ, Brouwer KL.

Drug Metab Dispos. 2013 Jun;41(6):1179-86. doi: 10.1124/dmd.112.048181. Epub 2013 Mar 12.

5.

Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment.

Frey R, Scheerans C, Blunck M, Mück W, Gnoth MJ, Unger S, Schmidt A, Wensing G.

J Clin Pharmacol. 2012 Nov;52(11):1714-24. doi: 10.1177/0091270011426143. Epub 2011 Dec 12.

PMID:
22162535
6.

In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.

Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S.

J Pharmacol Exp Ther. 2011 Jul;338(1):372-80. doi: 10.1124/jpet.111.180240. Epub 2011 Apr 22.

PMID:
21515813
7.

Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions.

Muenster U, Pelzetter C, Backensfeld T, Ohm A, Kuhlmann T, Mueller H, Lustig K, Keldenich J, Greschat S, Göller AH, Gnoth MJ.

Eur J Pharm Biopharm. 2011 Aug;78(3):522-30. doi: 10.1016/j.ejpb.2011.01.023. Epub 2011 Feb 16.

PMID:
21315152
8.

In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.

Gnoth MJ, Sandmann S, Engel K, Radtke M.

Drug Metab Dispos. 2010 Aug;38(8):1341-6. doi: 10.1124/dmd.110.032052. Epub 2010 Apr 22.

PMID:
20413726
9.

A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors.

Wunder F, Gnoth MJ, Geerts A, Barufe D.

Mol Pharm. 2009 Jan-Feb;6(1):326-36. doi: 10.1021/mp800127n.

PMID:
19049345
10.

Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.

Schirok H, Kast R, Figueroa-Pérez S, Bennabi S, Gnoth MJ, Feurer A, Heckroth H, Thutewohl M, Paulsen H, Knorr A, Hütter J, Lobell M, Münter K, Geiss V, Ehmke H, Lang D, Radtke M, Mittendorf J, Stasch JP.

ChemMedChem. 2008 Dec;3(12):1893-904. doi: 10.1002/cmdc.200800211.

PMID:
18973168
11.

Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.

Muenster U, Grieshop B, Ickenroth K, Gnoth MJ.

Pharm Res. 2008 Oct;25(10):2320-6. doi: 10.1007/s11095-008-9632-1. Epub 2008 Jun 4.

PMID:
18523872
12.

Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.

Kast R, Schirok H, Figueroa-Pérez S, Mittendorf J, Gnoth MJ, Apeler H, Lenz J, Franz JK, Knorr A, Hütter J, Lobell M, Zimmermann K, Münter K, Augstein KH, Ehmke H, Stasch JP.

Br J Pharmacol. 2007 Dec;152(7):1070-80. Epub 2007 Oct 15.

13.

Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.

Evgenov OV, Kohane DS, Bloch KD, Stasch JP, Volpato GP, Bellas E, Evgenov NV, Buys ES, Gnoth MJ, Graveline AR, Liu R, Hess DR, Langer R, Zapol WM.

Am J Respir Crit Care Med. 2007 Dec 1;176(11):1138-45. Epub 2007 Sep 13.

14.

Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.

Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT.

Circulation. 2006 Jan 17;113(2):286-95. Epub 2006 Jan 3.

PMID:
16391154
15.

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.

Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM.

Circulation. 2004 Oct 12;110(15):2253-9. Epub 2004 Oct 4.

PMID:
15466650
16.
17.

Endotoxin-reduced milk oligosaccharide fractions suitable for cell biological studies.

Gnoth MJ, Kunz C, Rudloff S.

Eur J Med Res. 2000 Nov 30;5(11):468-72.

PMID:
11121367
18.

Human milk oligosaccharides are minimally digested in vitro.

Gnoth MJ, Kunz C, Kinne-Saffran E, Rudloff S.

J Nutr. 2000 Dec;130(12):3014-20.

PMID:
11110861

Supplemental Content

Loading ...
Support Center